Eterna Therapeutics INC Schedule 13G passive stakes

Clear Street LLC has filed an amendment to its Schedule 13G to terminate its reporting obligation for Ernexa Therapeutics Inc. as its beneficial ownership has fallen below the 5% threshold.

Freebird Partners LP and affiliates have filed an amended Schedule 13G reporting a 9.9% beneficial ownership stake in Ernexa Therapeutics Inc.

John and Katherine Halpern have filed an amended Schedule 13G reporting a 5.6% beneficial ownership stake in Ernexa Therapeutics Inc.

Bleichroeder LP and Andrew Gundlach have filed a Schedule 13G reporting a 6.86% beneficial ownership stake in Ernexa Therapeutics Inc.

Clear Street LLC has reported beneficial ownership of 149,499 shares, representing 12.8% of the outstanding common stock of Ernexa Therapeutics Inc.

Shameek and Victoria Konar, through Regolith Capital Investments, have reported a 9.7% beneficial ownership in Ernexa Therapeutics following significant share consolidations.

Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff updated their beneficial ownership in Ernexa Therapeutics Inc. to 9.9% following a reverse stock split.

Shameek Konar, Victoria Konar, and Regolith Capital Investments LP collectively report beneficial ownership of 7.12% of Ernexa Therapeutics Inc. common stock.

IAF, LLC has reduced its beneficial ownership in Ernexa Therapeutics Inc. to below 5%, triggering an exit filing.

John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, have disclosed a 9.6% beneficial ownership stake in Eterna Therapeutics Inc., with additional shares pending stockholder approval.

Shameek Konar, Victoria Konar, and Regolith Capital Investments LP have disclosed beneficial ownership of 5.5% of Ernexa Therapeutics Inc.'s common stock, with additional shares pending stockholder approval.

IAF, LLC has reported a 5.2% beneficial ownership stake in Ernexa Therapeutics Inc., holding 3,255,421 shares of common stock as a passive investor.

Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff have jointly disclosed a 9.9% beneficial ownership stake in Ernexa Therapeutics Inc., with additional shares pending shareholder approval.

Nicholas Jason Singer and Purchase Capital LLC have filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of 2,565,001 shares, or 4.92%, of Eterna Therapeutics Inc.'s common stock as of December 31, 2024.

John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, have reported a 9.99% beneficial ownership stake in Eterna Therapeutics Inc. common stock.

IAF, LLC has filed an amended Schedule 13G, reporting beneficial ownership of 5.22% of Eterna Therapeutics Inc.'s common stock as of October 29, 2024.

Freebird Partners LP, Freebird Investments LLC, and Curtis W. Huff have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.99% of Eterna Therapeutics Inc.'s common stock as of October 29, 2024.